Collins et al., 1984 - Google Patents
Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human), and potentiation of antibiotic protection against …Collins et al., 1984
- Document ID
- 14934162854320312489
- Author
- Collins M
- Dorsey J
- Publication year
- Publication venue
- The American journal of medicine
External Links
Snippet
Immunoglobulin G intravenous is prepared by controlled reduction and alkylation of approximately four interheavy chain disulfide bonds per molecule. To determine if the protective activity of antibody modifed by this process is diminished, mice were treated with …
- 108090001095 Immunoglobulin G 0 title abstract description 48
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andreoli et al. | Role of glutathione in protecting endothelial cells against hydrogen peroxide oxidant injury | |
| Cudmore et al. | Clostridium difficile colitis associated with cancer chemotherapy | |
| Liu et al. | Staphylococcal peptidoglycans induce arthritis | |
| US8629100B2 (en) | Method of inhibiting clostridium difficile by administration of oritavancin | |
| Tan et al. | Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia | |
| Fischer et al. | Enhanced host defense mechanisms with levamisole in suckling rats | |
| Schwartz et al. | Patient protection in cancer chemotherapy | |
| Pennington et al. | Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia | |
| Nathan et al. | Burn wounds: microbiology, local host defenses, and current therapy | |
| Cross et al. | The efficacy of combination immunotherapy in experimental Pseudomonas sepsis | |
| Alexander | Host defense mechanisms against infection | |
| Collins et al. | Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human), and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo | |
| Alexander | Antibiotic agents and the immune mechanisms of defense | |
| Alexander | Nosocomial infections | |
| Trautmann et al. | Listeria meningitis: report of ten recent cases and review of current therapeutic recommendations | |
| HILL | Intravenous immunoglobulin use in the neonate: role in prophylaxis and therapy of infection | |
| Yang et al. | Mechanisms of bacterial opsonization by immune globulin intravenous: correlation of complement consumption with opsonic activity and protective efficacy | |
| Boros et al. | Effect of antimacrophage serum on hypersensitivity (Schistosoma mansoni egg) and foreign body (divinyl-benzene copolymer bead) granulomas | |
| Cates | Host factors in bacteremia | |
| Hill et al. | Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci | |
| Hill et al. | Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens | |
| Winkelstein et al. | Phagocytosis: the normal process and its clinically significant abnormalities | |
| Menday et al. | Intravenous fusidic acid ('Fucidin') in the management of severe staphylococcal infections: a review of 46 cases | |
| Rule et al. | Pharmacokinetics of ceftazidime administered to lactating and non-lactating goats | |
| WAISBREN et al. | Antibiotics and gamma-globulin in Pseudomonas infections |